Research for Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) - aVenture Research
PR Newswire
Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, Shanghai Henlius Biotech, Inc ("Henlius"), a global, innovation-driven biopharmaceutical company, announced at the European Society for Medical Oncology (ESMO) Congress 2026, positive results from ASTRIDE, a randomized, descriptive, open-label, U.S. study of serplulimab (in Europe, Hetronifly®), an anti-PD-1 monoclonal antibody (mAb), in combination with carboplatin and etoposide (chemotherapy) compared to atezolizumab plus chemotherap